Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2012

01-09-2012 | Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies

Authors: Alan R. Lifson, Harry A. Lando

Published in: Current HIV/AIDS Reports | Issue 3/2012

Login to get access

Abstract

Health hazards due to smoking may undermine benefits of HIV treatment on morbidity and mortality. Over 40 % of persons with HIV are current smokers. Health risks of smoking include increases in some HIV-associated infections, cardiovascular disease, some cancers, bacterial pneumonia and other lung disease, and overall mortality. Proven strategies for smoking cessation include various counseling approaches, nicotine replacement therapy and other pharmacotherapy; approaches may need to be individualized to address specific client needs and comorbidities. HIV clinicians and other service providers can have an influential role in screening their patients for smoking and promoting cessation programs to improve health.
Literature
1.
CDC. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥18 Years --- United States, 2005--2010. MMWR 2011; 60:1207–12.
2.
• Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health 2010;100:1896–903. For HIV patients enrolled from 33 countries in a large HIV clinical trial, this reports on the relationship between smoking status and development of AIDS-related or serious non-AIDS events and overall mortality. PubMedCrossRef
3.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV-positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824–35.PubMedCrossRef
4.
• Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev. 2009;21(3 Suppl):40–53. A study evaluating overall mortality in veterans, stratified by HIV and smoking, which concluded that even lower levels of smoking exposure appear to be detrimental in HIV-infected veterans. PubMedCrossRef
5.
Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS. 2007;21:458–68.PubMedCrossRef
6.
Broom J, Sowden D, Williams M, Taing K, Morwood K, McGill K. Moving from viral suppression to comprehensive patient-centered care: the high prevalence of comorbid conditions and health risk factors in HIV-1-infected patients in Australia. J Int Assoc Physicians AIDS Care. 2012;11:109–14.CrossRef
7.
• Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med 2011;12: 412–21. This study concluded that the risk of cardiovascular disease events in HIV-positive patients decreased with increasing time since stopping smoking. PubMedCrossRef
8.
Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. HIV-positive smokers considering quitting: differences by race/ethnicity. Am J Health Behav. 2008;32:3–15.PubMedCrossRef
9.
Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the Women’s Interagency HIV Study. Am J Public Health. 2006;96:1060–5.PubMedCrossRef
10.
11.
12.
Kumar SR, Swaminathan S, Flanigan T, Mayer KH, Niaura R. HIV and smoking in India. Indian J Med Res. 2009;130:15–22.PubMed
13.
Amiya RM, Poudel KC, Poudel-Tandukar K, Kobayashi J, Pandey BD, Jimba M. Physicians are a key to encouraging cessation of smoking among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley. Nepal BMC Public Health. 2011;11:677.CrossRef
14.
Desalu OO, Oluboyo PO, Olokoba AB. et al Prevalence and determinants of tobacco smoking among HIV patients in North Eastern Nigeria. Afr J Med Med Sci. 2009;38:103–8.PubMed
15.
Nturibi EM, Kolawole AA, McCurdy SA. Smoking prevalence and tobacco control measures in Kenya, Uganda, the Gambia and Liberia: a review. Int J Tuberc Lung Dis. 2009;13:165–70.PubMed
16.
Burns DN, Hillman D, Neaton JD, et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:374–83.PubMedCrossRef
17.
Conley LJ, Bush TJ, Buchbinder SP, Penley KA, Judson FN, Holmberg SD. The association between cigarette smoking and selected HIV-related medical conditions. AIDS. 1996;10:1121–6.PubMed
18.
Soysa NS, Ellepola ANB. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis. 2005;11:268–73.PubMedCrossRef
19.
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8:313–9.PubMedCrossRef
20.
Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326–33.PubMedCrossRef
21.
Miguez-Burbano MJ, Ashkin D, Rodriguez A, et al. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis. 2005;9:208–17.PubMedCrossRef
22.
Crothers K, Griffith TA, McGinnis KA, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142–5.PubMedCrossRef
23.
World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings, 2011. At: whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf
24.
Slama K, Chiang CY, Enarson DA, et al. Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis. 2007;11:1049–61.PubMed
25.
Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med. 2007;167:335–42.PubMedCrossRef
26.
Van Zyl-Smit RN, Brunet L, Pai M, Yew WW. The convergence of the global smoking, COPD, tuberculosis, HIV, and respiratory infection epidemics. Infect Dis Clin North Am. 2010;24:693–703.PubMedCrossRef
27.
Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409–18.PubMedCrossRef
28.
US Dept of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
29.
Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther. 2003;25:2405–18.PubMedCrossRef
30.
Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.PubMedCrossRef
31.
Grunfeld C, Delaney JA, Wanke C, et al. Pre-clinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM Study. AIDS. 2009;23:1841–9.PubMedCrossRef
32.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.PubMedCrossRef
33.
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32.PubMedCrossRef
34.
Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev. 2003;12:638–42.PubMed
35.
Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr. 1994;7:599–606.PubMed
36.
Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383–8.PubMedCrossRef
37.
Kirk GD, Merlo C. O’ Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–10.PubMedCrossRef
38.
Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 2009;23:1297–310.PubMedCrossRef
39.
Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285–93.PubMedCrossRef
40.
Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women’s Interagency HIV Study. AIDS. 2010;24:2679–86.PubMedCrossRef
41.
42.
43.
Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annual Rev Med. 2011;62:141–55.CrossRef
44.
Zanet D, Sattha B, Maan E, et al. HIV infection is marginally associated with shorter leukocyte telomere length [Abstract 307]. 19th Conference of Retroviruses and Opportunistic Infections, Seattle, March 5–8, 2012.
45.
Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31:808–12.CrossRef
46.
Vidrine DJ. Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies. AIDS Educ Prev. 2009;21(3 Suppl):3–13.PubMedCrossRef
47.
Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS. AIDS Patient Care STDS. 2007;21:659–66.PubMedCrossRef
48.
Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS. 2002;16:39–42.PubMedCrossRef
49.
Prochaska JO, DiClemente CC. Toward a comprehensive model of change. In: Miller WR, Heather N, editors. Treating Addictive Behaviors: Processes of Change. New York: Plenum Press; 1986. p. 3–27.
50.
Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7:511–22.PubMedCrossRef
51.
Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21(3 Suppl):54–64.PubMedCrossRef
52.
• Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev 2009; 21(Suppl 3):106–21. This review of factors associated with smoking behavior includes a discussion of social conditions, polysubstance use, psychiatric comorbidities, physical-mental distress, and supporting beliefs, and how a self-regulatory framework relates to smoking behavior. PubMedCrossRef
53.
• Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009; 21(Suppl 3):14–27. This paper reviews health consequences of tobacco use in HIV-positive persons and the research to date on smoking cessation interventions in HIV-positive persons. PubMedCrossRef
54.
Nicholas PK, Voss JG, Corless IB, et al. Unhealthy behaviours for self-management of HIV-related peripheral neuropathy. AIDS Care. 2007;19:1266–73.PubMedCrossRef
55.
Jamner LD, Girdler SS, Shapiro D, Jarvik ME. Pain inhibition, nicotine, and gender. Exp Clin Psychopharmacol. 1998;6:96–106.PubMedCrossRef
56.
Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
57.
Manley MW, Epps RP, Glynn TJ. The clinician’s role in promoting smoking cessation among clinic patients. Med Clin North Am. 1992;76:477–94.PubMed
58.
Hollis JF, Lichtenstein E, Vogt TM, Stevens VJ, Biglan A. Nurse-assisted counseling for smokers in primary care. Ann Intern Med. 1993;118:521–5.PubMed
59.
Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans. J Gen Intern Med. 2007;22:749–54.PubMedCrossRef
60.
Patwardhan PD, Chewning BA. Ask, advise and refer: hypothesis generation to promote a brief tobacco-cessation intervention in community pharmacies. Int J Pharm Pract. 2009;17:221–9.PubMedCrossRef
61.
62.
63.
North American Quitline Consortium: Promoting Evidence Based Quitline Services Across Diverse Communities in North America. At: <www.​naquitline.​org>.
64.
Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV + smokers: a randomized controlled trial. Addiction. 2009;104:1891–900.PubMedCrossRef
65.
Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545–54.PubMedCrossRef
66.
Elzi L, Spoerl D, Voggensperger J, et al. A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther. 2006;11:787–95.PubMed
67.
Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS. 2006;20:253–60.PubMedCrossRef
68.
Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25:825–34.PubMedCrossRef
69.
Shahab L, McEwen A. Online support for smoking cessation: a systematic review of the literature. Addiction. 2009;104:1792–804.PubMedCrossRef
70.
Muramoto ML, Wassum K, Connolly T, Matthews E, Floden L. Helpers program: A pilot test of brief tobacco intervention training in three corporations. Am J Prev Med. 2010;38(3 Suppl):319–26.CrossRef
71.
• Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J 2009;6:25. This is a systematic review and meta-analysis of randomized clinical trials evaluating interventions for smoking abstinence, including nicotine replacement therapy and other pharmacologic agents. PubMedCrossRef
72.
Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146.
73.
Swan GE, McAfee T, Curry SJ. at al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003;163:2337–44.PubMedCrossRef
74.
Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.PubMedCrossRef
75.
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.PubMedCrossRef
76.
77.
78.
Centers for Disease Control and Prevention. State smoke-free laws for worksites, restaurants, and bars–United States, 2000–2010. MMWR Morb Mortal Wkly Rep. 2011;60:472–5.
79.
Robinson W, Moody-Thomas S, Gruber D. Patient perspectives on tobacco cessation services for persons living with HIV/AIDS. AIDS Care. 2012;24:71–6.PubMedCrossRef
Metadata
Title
Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies
Authors
Alan R. Lifson
Harry A. Lando
Publication date
01-09-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 3/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-012-0121-0

Other articles of this Issue 3/2012

Current HIV/AIDS Reports 3/2012 Go to the issue

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Renal Dysfunction in the Setting of HIV/AIDS

Co-infections (C Benson, Section Editor)

Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?

Co-infections (C Benson, Section Editor)

New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis

Co-infections (C Benson, Section Editor)

Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer?

Co-infections (C Benson, Section Editor)

Hepatitis C and HIV Co-Infection: New Drugs in Practice and in the Pipeline

Co-infections (C Benson, Section Editor)

Management of the Immune Reconstitution Inflammatory Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits